UNICREDIT BANK/CALL/ELI LILLY & CO/600/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 05:11:07 14/06/2024 pm IST | ||
| 27.95 EUR | +0.43% |
|
| Current month | +27.39% | ||
| 1 month | +58.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 27.95 | +0.43% |
| 13/24/13 | 27.83 | +5.66% |
| 12/24/12 | 26.34 | -1.09% |
| 11/24/11 | 26.63 | -0.15% |
| 10/24/10 | 26.67 | +5.92% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 05:11 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HC3L82 |
| ISIN | DE000HC3L829 |
| Date issued | 27/01/2023 |
| Strike | 600 $ |
| Maturity | 18/12/2024 (185 Days) |
| Parity | 10 : 1 |
| Emission price | 1.2 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 28.45 € |
|---|---|
| Lowest since issue | 0.38 € |
| Spread | 0.47 € |
| Spread % | 1.65% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant
